Kornimate/medical-research-clean huggingface dataset:
evaluation of text message engagement support of mindfulness smartphone applications

Conditions: Depression; Anxiety

Summary: the aim of this study is to assess the usability of two mindfulness smartphone applications (apps) and to evaluate whether text message support can promote engagement with those apps through a 4-week trial comparing support vs. no support.

part one of this study is to conduct usability testing to understand more about the acceptability and usability of these existing mindfulness apps in a population with depression and anxiety. the goal of usability testing is to identify any usability problems, provide information for future app development, and determine the participant's satisfaction with the apps. participants will then be randomized to receive either engagement support or no support which will be delivered via text messaging, and will be randomized to use one of the two mindfulness applications for the 4 week period. specific aim 2.1 is to evaluate any differences on outcome measures between the two mindfulness apps. specific aim 2.2 is to evaluate the differences of outcome measures between text message engagement support versus no support, regardless of the mindfulness app. for aim 2.1, the investigators predict that all mindfulness apps will be capable of leading to improvements on outcome measures. for aim 2.2, the investigators predict that the text message engagement support arm will engage more with the mindfulness app and will see greater improvements in outcome measures regardless of the mindfulness app.

Eligibility criteria:
inclusion criteria: 1. meet criteria for clinically significant distress caused by anxiety defined by a generalized anxiety disorder-7 (gad-7) greater than a 10 or clinically significant distress caused my depression defined by a patient health questionnaire (phq-9) greater than 10 2. 18 years of age or older; 3. fluent in english; 4. lives in the chicago area and are able to attend and in person session; 5. own an internet ready smartphone with data and text plans. exclusion criteria: 1. have visual, hearing, voice, or motor impairment that would prevent completion treatment procedures; 2. past or current diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, substance or alcohol abuse dependence, or other diagnosis for which participation in the trial would be dangerous; 3. suicidal, defined as a 1 or higher on item 9 of the patient health questionnaire (phq-9); 4. adults unable to consent.
application of huc-mscs in treating acute lung injury: a single center prospective clinical research

Conditions: Acute Lung Injury

Summary: the patients suffered from acute lung ininjury (200\<pao2/fio2 ≤ 300) will be divided into two groups: mscs-treated group: patients are treated by intravenous injection of huc-mscs suspention ; control group: patients were treated with vehicle(albumin) . the standard therapies of acute lung injury were the same in both groups. in the following-up days, all the patients were monitored by the same items to evaluate the therapeutic effects.


Eligibility criteria:
inclusion criteria: * 1.≤ 3 days (72h) * 2.age ≥18 years, ≤65 years * 3.200\<pao2/fio2 ≤ 300 * 4.chest x-ray/chest ct : infiltrates of both lungs * 5.need assisted ventilation (ventilation or high flow oxygen therapy) * 6.no left heart failure, pulmonary edema * 7.agree to participate and signe an informed consent exclusion criteria: * 1.life expectancy \<3 months due to non-respiratory failure * 2.patients receiving extracorporeal membrane oxygenation support therapy(ecmo),high frequency oscillatory ventilation * 3.history of hiv, malignant tumors, or impaired immune function * 4.patients accepted major surgery in the past 14 days (such as tumor removal, thoracotomy, heart surgery, abdominal surgery, intracranial surgery, or surgery for more than 3 hours, etc.) * 5.pregnancy * 6.have a serious concomitant disease * 7.unable to follow-up * 8.history of severe allergic reactions or allergy to saline and serum * 9.already participated in another clinical study within 12 weeks * 10.pulmonary edema caused by other underlying diseases
polymorphism of estrogen genes in stroke

Conditions: Ischemic Stroke

Summary: the purpose of this study is to explore the association between the genetic polymorphisms of estrogen-related genes, including estrogen synthesis, metabolizing, and receptor genes, and ischemic stroke. furthermore, independent and joint effects of traditional risk factors and estrogen related genes on risk of stroke in young adults will also be examined in this study.

cerebrovascular diseases are the third leading cause of death in taiwan in 2007. it is also the most important reason for disability among elderly adults. sex hormones are well reported to be associated with cardiovascular disease risk. several studies showed that estrogens have been shown to have beneficial effects on the cardiovascular system via favorable effects on anti-inflammatory effects. genetic polymorphisms of estrogen related genes are speculated to influence estrogen level and will count for human susceptible to risk of stroke in young adults. in addition, several studies showed that the decrease in estrogen-induced vascular inflammatory markers including adhesion molecules and chemokines might be the mechanism for vascular protection. recently, a novel and unique mechanisms for 17β-estradiol (e2) anti-inflammatory activity which is e2 prevents inflammatory gene transcription induced by inflammatory agents by inhibiting nf-κb intracellular transport was found. therefore, we proposed a study to explore the association between the genetic polymorphisms of estrogen-related genes, including estrogen synthesis, metabolizing, receptor genes, and nf-κb and ischemic stroke in young adults.

Eligibility criteria:
inclusion criteria: * incident ischemic stroke patients diagnosed by ct or mri. exclusion criteria: * non ischemic stroke patients

Keywords: ischemic stroke patients
doxycycline in type ii diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: type 2 diabetes mellitus (t2dm) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. t2dm develops due to the progression of insulin resistance (ir), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden


Eligibility criteria:
inclusion criteria: * male or female sex more than 40 years old newly diagnosed type ii diabetes. hba1c more than 6.5 exclusion criteria: * patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
dexamethasone for treatment of radiation-related fatigue in patients receiving rt for head-neck and lung cancer

Conditions: Head and Neck Cancer; Non-small Cell Lung Cancer

Summary: this study will look at how dexamethasone and placebo influence radiation fatigue, quality of life and number of treatment days missed during radiation therapy or radiation therapy and chemotherapy for cancer.

subjects will randomly receive either dexamethasone or placebo and begin the study medication during the midpoint of their radiation treatment. study medication will be taken for 14 straight days then stopped. fatigue and quality of life will be measured weekly with short patient completed surveys. the number of breaks taken during radiation treatment will also be tracked. for safety, blood sugar levels will be checked with finger stick blood draws because dexamethasone is known to cause these levels to increase. study participation will be approximately 3 months.

Eligibility criteria:
inclusion criteria: * confirmation of head \& neck cancer (stage i-iv) or non-small cell lung cancer (stage ii \& iii) * undergoing treatment with either radiation alone or in combination with chemotherapy * normal cognition and willingness to complete fatigue and quality of life forms, patient observation form, and pill diary exclusion criteria: * hypersensitivity to dexamethasone or corticosteroids or equal sugar substitute * corticosteroid within the past 30 days prior to study enrollment for greater than one week duration * planned stereotactic body radiation therapy (sbrt) * active psychosis * current pregnancy * active peptic ulcer disease or evidence of gastrointestinal bleed * current active tuberculosis or systemic fungal infection * previous diagnosis of diabetes mellitus * acute febrile illness * known human immunodeficiency virus or acquired immunodeficiency syndrome * major surgery within two weeks of study enrollment of which the patient has not recovered * psychostimulant use in the past 30 days prior to registration * history of phenylketonuria (pku)

Keywords: cancer radiation therapy chemotherapy dexamethasone corticosteroids
pharmacokinetics of oxytocin at cesarean delivery

Conditions: Postpartum Hemorrhage

Summary: the primary objective is to obtain data to inform the design of a population pharmacokinetic study of oxytocin after administration at cd as per standard institutional practice.

in this pilot study the investigators will compare plasma oxytocin concentrations measured in arterial and venous blood, after oxytocin administration at cesarean delivery, in order to assess the validity of venous samples. they will also measure oxytocinase to explore how levels vary around the time of delivery of the placenta and to assess the effect that this may have on the metabolism of oxytocin.

Eligibility criteria:
inclusion criteria: * term singleton pregnancy * age 18-45 years of age * asa classification 2 or 3 * scheduled cesarean delivery under neuraxial anaesthesia exclusion criteria: * age or asa classification outside of inclusion criteria * need for general anaesthesia * absence of consent * inability to communicate in english or other barrier to providing informed consent
a study to investigate how jnj-38518168 may affect the plasma levels of methotrexate in rheumatoid arthritis participants

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the effects of jnj-38518168 on the pharmacokinetics (how the body handles a drug) of methotrexate in participants with rheumatoid arthritis.

this is an open-label (physician and participant will know the name of the assigned drug), multi-center, non-randomized, drug/drug interaction study of jnj-38518168 in participants with rheumatoid arthritis (ra) on a stable oral methotrexate (mtx) dose (7.5-25 mg). the treatment phase will last 16 days. participants will be housed in the clinic for dosing and study procedures from day -1 to day 2 and again from day 14 to day 16. participants completing treatment will have a follow-up visit between days 22 and 25. participants who discontinue the study prematurely will complete the day 22 to 25 follow-up procedures at the time of discontinuation or as soon as possible thereafter. the duration of participation in the study for an individual participant will be up to 7 weeks (including screening). participant safety will be monitored. day 1: a single oral dose of the participant's weekly methotrexate dose. days 2-15: weekly mtx co-administered with two 50-mg capsules of jnj-38518168, administered daily.

Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) between 18 and 38 kg/m2 inclusive, and a body weight between 50-110 kg, inclusive * have a diagnosis of rheumatoid arthritis functional class i-iii for at least 3 months prior to screening * have been treated with and tolerated oral mtx treatment for a minimum of 3 months prior to screening and must have been on a once-weekly stable mtx dose (taken as a single dose) (between 7.5-25 mg/week) for a minimum of 1 month * participants may continue on stable non-steroid anti-inflammatory drugs and corticosteroid background therapy for ra or stable therapies for other conditions as prescribed by physician, provided that the doses of such therapy are stable for at least 1 month prior to screening and will remain unchanged for the entire study duration. exclusion criteria: * have current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive or uncontrolled in the study doctor's opinion * have been treated with a monoclonal antibody for ra or have had a serious infection with 2 weeks of the study treatment period.

Keywords: rheumatoid arthritis jnj-38518168 methotrexate
coping with shift work - web based program for police officers

Conditions: Sleep Disorders; Stress

Summary: this study is a clinical trial in which 300 police officers who currently work midnight shifts in the participating police departments will be recruited to test the effectiveness of a new web-based program to address sleep and associated problems related to shift work, particularly night shift work. recruitment letters will be sent to all officers currently working midnight shift, with the goal of recruiting 300 officers willing to participate in the study. the 300 participants will be randomly assigned to either the experimental group (receiving the web-based program) or the waitlist control group. participants in the experimental group will be given access to the program site (coping with shift work) and the mobile application (sleep tracker). following completion of the field test, participants in the control condition (as well as all other interested officers) will have access to the web-based coping with shift work program. all participants will be asked to complete a baseline questionnaire containing multiple measures of sleep, dietary practices, physical activity and job performance. participants will be asked to complete the posttest approximately three months following initial access to the intervention. primary and secondary outcome measures: the primary outcome measures are "sleep quality" as measured by the pittsburgh sleep quality index (psqi) and "sleepiness" as measured by the sleepiness subscale of the widely used karolinska sleep questionnaire (ksq). the investigators have adapted the sleep measures to apply to individuals who work nights and may sleep during the day. secondary outcome measures include the nutritional patterns scale, a 13-item modification of the block self-administered diet history questionnaire assessing the nutritional value of the respondent's diet; attitudes toward a healthy diet, a 17-item scale, based on the health belief model and developed and validated by trenkner and associates assessing perceived benefits and barriers to eating a healthy diet; the godin leisure-time exercise questionnaire, a brief 4-item query of usual leisure-time exercise habits; and work productivity measured with the work limitations questionnaire (wlq), developed and validated by lerner and associates. it is expected that the program group participants will have significantly better outcomes than the control group at three months.


Eligibility criteria:
inclusion criteria: * police officer with participating police departments * access to a computer or mobile device with internet access exclusion criteria: * none

Keywords: shiftwork sleep disruption stress
right ventricular dysfunction in septic shock patients in icu

Conditions: Septic Shock

Summary: assesment of right ventricular dysfunction in septic shock patients in intensive care unit.

over the last decade, a few studies have highlighted the crucial role of right ventricular (rv) function in hemodynamic and respiratory diseases in critical care 1,2. however, rv failure is difficult to define in the critical care setting. a recent consensual definition proposed by different groups of experts characterizes rv failure as the association of a significant rv dilatation associated with systemic congestion 3-5. this definition is mainly physiologically based, not strictly validated, and the experts did not propose any threshold for rv size or congestion using critical care echocardiography (cce) and central venous pressure (cvp), respectively. fluid management in septic shock is crucial for prognosis, as fluid overload and high cvp are associated with a worse outcome 6. septic shock is expected to impair rv function through the development of septic cardiomyopathy, but the incidence of rv failure is unknown.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with septic shock. 2. patients will be evaluated within 24 h after diagnosis. exclusion criteria: 1. patients diagnosed more than 24 hours. 2. patients with associated ischemic heart failure .
polycystic ovarian syndrome: impact of flaxseed supplementation

Conditions: Polycystic Ovarian Syndrome

Summary: the overall aim of this study is to explore the effects of flaxseed supplementation and determine whether it is a feasible and potentially effective dietary intervention among women with polycystic ovarian syndrome (pcos). women, ages 18-45, with clinically confirmed pcos (n=20) will be scheduled for baseline measures and then instructed and given supplies necessary to follow a flaxseed supplemented (30 g/day) diet for a period of three months, whereupon follow-up measures will be taken. subjects will be asked to resume their typical (unsupplemented) diet for another three months and a second set of follow-up measures will be taken. baseline levels of bioavailable and total testosterone, fasting insulin, glucose, and triglycerides (tg), total/ldl/hdl cholesterol, body weight, degree of hirsutism and acne, and menstrual cyclicity will be compared to levels at 3 and 6 month follow-up. the overall hypothesis (based upon our work in men at risk for prostate cancer and data from one case-study conducted in a woman with confirmed pcos) is that during the time women receive flaxseed supplementation they will experience reduced serum levels of testosterone, and total and ldl cholesterol, as well as clinical evidence of hirsutism. given the pilot nature of this study, statistical analyses will be limited to simple descriptive statistics. we have observed no negative side effects, other than minor gastro-intestinal occurrences (i.e., temporary increased flatulence, borborygmi, increased number of stools, etc.) associated with flaxseed supplementation in our previous studies either with short or long-term use. flaxseed supplementation will be discontinued if indicated and the events reported to the institutional review board.


Eligibility criteria:
inclusion criteria: * limited to women aged 18-45 * diagnosis of pcos by menstrual irregularity (fewer than 9 menses annually), ferriman-gallwey score \> 8, and/or hyperandrogenemia defined as bioavailable t\>8.4ng/dl (zawdaki \& dunaif 1992) * mentally competent * english speaking/writing * telephone access and/or email access exclusion criteria: * use of oral contraceptives, spironolactone or insulin-sensitizing agents within the past 3 months; * long-term or chronic use of oral antibiotics; * diagnoses of hyperprolactinemia, thyroid abnormalities, or nonclassic adrenal hyperplasia; * hysterectomy; * onset of menopause; * pregnancy/lactation; * consumption of flaxseed within the past month; and * use of any dietary fiber supplements which are newly started (within the past 6 months) and agreement not to use any new fiber supplements during the study period

Keywords: pcos flaxseed
azithromycin in the treatment of cryptosporidiosis in patients with acquired immune deficiency syndrome (aids): a randomized, multi-center, placebo-controlled, double-blind study

Conditions: Cryptosporidiosis; HIV Infections

Summary: to evaluate the safety and efficacy of azithromycin in the treatment of intestinal cryptosporidial infection in aids patients.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine. * antidiarrheal medication with imodium or paregoric only. patients must have: * hiv infection. * intestinal cryptosporidiosis proven by stool microscopy on at least two occasions prior to study enrollment. * life expectancy of at least 2 weeks by clinical assessment. in states where the legal age of consent for medical procedures is 21 years, patients below the age of 21 must have consent of parent or guardian. prior medication: allowed: * zidovudine. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * known hypersensitivity or significant intolerance to macrolide antibiotics. * marked abnormalities of liver or renal function. * causes for diarrhea other than, or in addition to, cryptosporidiosis. * inability to receive oral medication. concurrent medication: excluded: * cancer chemotherapy (including therapy for kaposi's sarcoma). * any drug or biologic preparation (e.g., bovine colostrum, paromomycin, spiramycin, somatostatin) with possible anticryptosporidial activity. * immunostimulant or lymphocyte replacement therapy. prior medication: excluded: * another investigational drug within 7 days prior to study enrollment (investigational medications available through a treatment ind will be allowed with the approval of the sponsor, the treatment ind sponsor, and the pfizer clinical monitor). * immunostimulant or lymphocyte replacement therapy. * cancer chemotherapy (including therapy for kaposi's sarcoma). not expected to comply with the requirements of the protocol, in the opinion of the investigator.

Keywords: cryptosporidiosis acquired immunodeficiency syndrome azithromycin
metformin/atorvastatin combination therapy in subjects with type ii diabetes and dyslipidemia (phase 3)

Conditions: Type II Diabetes; Dyslipidemia

Summary: a multi-center, randomized, double-blind, active-controlled, phase 3 trial to evaluate the safety and efficacy of metformin/atorvastatin in subjects with type ii diabetes and dyslipidemia.


Eligibility criteria:
inclusion criteria: * subjects with dyslipidemia and type ii diabetes * 19 years later, men and women under the age of 80 exclusion criteria: * pregnant women, nursing mothers or subject who does not agree to assigned contraception in the study * subject with type i diabetes * subject with hypertension which does not controlled by treatment(have blood pressure \> 180/110mmhg)
different modes of temperature measurement in the emergency department

Conditions: Sepsis

Summary: introduction: temperature measurement is a crucial and integral element in the assessment of the emergency department patients. the basis of triage and treatment is often directly influenced by temperature measurement. the finding of hyper/hypothermia may differentiate between a simple urinary tract infection and pyelonephritis, or in more extreme cases may discern "weakness" in the elderly from sepsis. this brief encounter of temperature measurement may be paramount to the medical treatment of the emergency department patient. the investigators will explore the different modes of temperature measurements in emergency department patients.

temperature measurement is a crucial and integral element in the assessment of the emergency department patients. the basis of triage and treatment is often directly influenced by temperature measurement. the finding of hyper/hypothermia may differentiate between a simple urinary tract infection and pyelonephritis, or in more extreme cases may discern "weakness" in the elderly from sepsis. this brief encounter of temperature measurement may be paramount to the medical treatment of the emergency department patient.we will explore the different modes of temperature measurements in emergency department patients. we will check which temperature measurement is beneficial.

Eligibility criteria:
inclusion criteria: * patients who arrive to the emergency department exclusion criteria: * patients who refuse

Keywords: temperature